The nation of Zimbabwe has rejected a substantial American health deal valued at 367 million US dollars (272 million pounds) over five years over Washington's insistence on sensitive biological samples.
The decision was revealed after a government memo dated December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
A government spokesman has since explained that the US was requesting health data for scientific study and profit but refused to share the benefits from future medical innovations.
"We must now begin the challenging and unfortunate task of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for further negotiations to reach a agreement suitable to both sides so the nation's vital HIV programme can continue.
Wider Implications
This rejection comes after a comparable case in neighbouring Kenya, where a high court suspended a related health funding agreement after concerns were filed about the security of citizens' medical information.
After returning to the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government deals to enhance openness and accountability.
As per reports, 16 African countries have so far signed these new agreements, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
The money for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation would have delivered extraordinary advantages for Zimbabwean communities, particularly the 1.2 million currently receiving HIV treatment through US-supported initiatives," Tremont commented.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no equivalent guarantee of benefiting from any medical innovations – such as new medicines or tests – that might be developed from that provided information," Mangwana explained.
"Effectively, our country would supply the raw materials for scientific discovery with no certainty that the final treatments would be accessible to our people should a future disease outbreak emerge."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were undermining systems already set up through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to deal with potential global health emergencies.
"This framework is intended to ensure that when a nation provides its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
These objections over the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage ongoing dialogue with our American counterparts on how subsequent co-operation could be designed in a manner that respects the sovereignty and dignity of both nations."
Health Experts Reaction
Medical experts stated it recognised the official position, but recommended that negotiations need to persist since a large portion of the country's Aids initiatives depended on international support.
"Where specific concerns exist, such as those relating to information security or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," the group added.
This impasse highlights the ongoing challenges between accepting much-needed foreign assistance and protecting a country's data in an ever more data-driven world.